1. Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience
- Author
-
Narendra Kumar, Srinivasa GY, Chinna B Dracham, Treshita Dey, Renu Madan, Divya Khosla, Arun Oinum, and Rakesh Kapoor
- Subjects
3D-conformal radiotherapy (3D-CRT) ,adjuvant TMZ ,cochlea ,concurrent temozolomide (TMZ) ,conformity index ,dose spillage ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Aim: The purpose of the study is to perform a dosimetric analysis of the doses received by planning target volume and organ at risks in the postoperative glioblastoma by using 3D-conformal radiotherapy to a total dose of 60 Gy in 30 fractions. Materials & Methods: All patients received concurrent temozolomide every day, and this was followed by adjuvant temozolomide of 5 days of treatment per month. Results: More than 98% of patients were treated with a dose of 60 Gy. Doses were analyzed for the normal whole brain, tumor volume, as well as all the organs at risk. Conclusion: Given the grave prognosis and the limited survival of glioblastoma despite the best treatment available, makes 3D-conformal radiotherapy an equally acceptable treatment option.
- Published
- 2020
- Full Text
- View/download PDF